Tarsus Pharmaceuticals (NASDAQ:TARS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS) in a research report released on Wednesday,Benzinga reports. HC Wainwright currently has a $73.00 price target on the stock.

A number of other equities research analysts also recently commented on TARS. Guggenheim restated a “buy” rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday. The Goldman Sachs Group increased their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Barclays lifted their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Finally, Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $61.33.

Tarsus Pharmaceuticals Trading Up 3.1 %

NASDAQ:TARS opened at $42.56 on Wednesday. Tarsus Pharmaceuticals has a 12-month low of $20.08 and a 12-month high of $57.28. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock’s 50 day simple moving average is $51.31 and its 200-day simple moving average is $43.00. The firm has a market cap of $1.63 billion, a P/E ratio of -11.17 and a beta of 1.01.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. Equities analysts anticipate that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Toronto Dominion Bank acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth $105,714,000. GF Fund Management CO. LTD. purchased a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Tarsus Pharmaceuticals by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company’s stock valued at $3,866,000 after buying an additional 10,991 shares during the period. Finally, Woodline Partners LP increased its stake in Tarsus Pharmaceuticals by 52.3% during the fourth quarter. Woodline Partners LP now owns 108,986 shares of the company’s stock worth $6,035,000 after acquiring an additional 37,417 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.